Sharp Therapeutics Corp.
SHRXF
$1.58
-$0.08-4.81%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -626.88% | -59.73% | 130.97% | -164.60% | 148.33% |
| Total Depreciation and Amortization | -48.90% | 472.73% | 177.11% | -36.26% | 73.28% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 146.11% | 388.82% | -397.03% | 218.69% | -570.69% |
| Change in Net Operating Assets | 461.24% | 36.95% | -94.67% | -323.89% | -344.94% |
| Cash from Operations | 33.47% | -28.50% | -98.25% | -132.03% | -215.02% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | 100.00% |
| Total Debt Repaid | 82.57% | 0.00% | 0.00% | 0.00% | -473.60% |
| Issuance of Common Stock | -99.31% | -- | -- | -- | 316.69% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -100.31% | -- | 102.68% | -111.11% | 915.28% |
| Foreign Exchange rate Adjustments | -834.43% | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -132.16% | -4,008.11% | 2,873.49% | -710.71% | 9,236.81% |